1672.HK
Ascletis Pharma Inc.
HKSEHKDEQUITY
DELAYED
Last price
10.02
▼ 0.23 (2.24%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
10.15
Prev close
10.25
Day high
10.32
Day low
9.95
Volume
1.78M
Market cap
—
P/E (TTM)
—
52W range
7.95 – 19.86
Day trading desk
Gap from prior close
-0.98%
Prior close 10.25
VWAP
10.02
+0.00% from price
Relative volume
—
—
Session range
3.77%
9.94 – 10.32
Position in range
20%
Near session low
ATR (14D)
0.66
6.59% of price
Prior day high
10.62
PDH
Prior day low
9.56
PDL
Bid / ask spread
—
Quote not published
Session volume
3.91M
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.02%
-3.7%
1M
+13.35%
+9.6%
3M
-33.69%
-36.8%
6M
-40.50%
-51.6%
YTD
-12.11%
-24.4%
1Y
-31.09%
-51.1%
3Y
+391.18%
+317.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on 1672.HK open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.03M | $1.28M | $56.60M | $54.09M | +58.1% |
| Operating revenue | $2.03M | $1.28M | $56.60M | $54.09M | +58.1% |
| Cost of revenue | $1.50M | $548.00K | $30.61M | $78.78M | +173.9% |
| Gross profit | $527.00K | $735.00K | $25.99M | -$24.69M | -28.3% |
| Research & development | $409.05M | $302.39M | $216.78M | $267.10M | +35.3% |
| Selling, general & admin | $30.27M | $55.56M | $62.96M | $21.19M | -45.5% |
| Total operating expense | $447.02M | $382.99M | $326.20M | $314.94M | +16.7% |
| Operating income | -$446.50M | -$382.25M | -$300.21M | -$339.63M | -16.8% |
| Net interest income | $65.51M | $91.99M | $99.13M | $44.01M | -28.8% |
| Pre-tax income | -$359.37M | -$300.94M | -$144.72M | -$314.84M | -19.4% |
| Tax provision | $506.00K | $0 | $0 | $0 | — |
| Net income | -$359.88M | -$300.94M | -$144.72M | -$314.84M | -19.6% |
| Net income to common | -$359.88M | -$300.94M | -$144.72M | -$314.84M | -19.6% |
| Basic EPS | -0.37 | -0.30 | -0.13 | -0.29 | -23.2% |
| Diluted EPS | -0.37 | -0.30 | -0.13 | -0.29 | -23.2% |
| EBIT | -$359.21M | -$300.69M | -$144.57M | -$314.69M | -19.5% |
| EBITDA | -$341.59M | -$280.24M | -$126.09M | -$284.50M | -21.9% |
| Basic shares | 972.51M | 1.00B | 1.07B | 1.09B | -2.9% |
| Diluted shares | 972.51M | 1.00B | 1.07B | 1.09B | -2.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.44B | $865.73M | $330.12M | $403.77M | +66.7% |
| Cash & short-term investments | $1.90B | $1.95B | $2.30B | $2.48B | -2.4% |
| Accounts receivable | $223.00K | $152.00K | $5.43M | $23.87M | +46.7% |
| Inventory | $1.87M | $4.37M | $6.07M | $20.52M | -57.1% |
| Total current assets | $1.92B | $1.97B | $2.33B | $2.54B | -2.5% |
| Property, plant & equipment | $46.96M | $57.20M | $68.54M | $73.04M | -17.9% |
| Goodwill & intangibles | $10.29M | $12.12M | $26.32M | $16.56M | -15.1% |
| Total assets | $2.07B | $2.12B | $2.49B | $2.66B | -2.7% |
| Total current liabilities | $127.59M | $153.05M | $140.68M | $108.19M | -16.6% |
| Total debt | $5.16M | $7.63M | $8.42M | $4.24M | -32.4% |
| Total liabilities | $132.26M | $158.41M | $148.94M | $117.16M | -16.5% |
| Retained earnings | -$1.84B | -$1.48B | -$1.17B | -$1.03B | -24.4% |
| Shareholder equity | $1.93B | $1.97B | $2.34B | $2.54B | -1.6% |
| Working capital | $1.79B | $1.82B | $2.19B | $2.44B | -1.4% |
| Net tangible assets | $1.92B | $1.95B | $2.32B | $2.52B | -1.5% |
| Shares issued | 998.96M | 1.01B | 1.04B | 1.09B | -1.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$359.37M | -$300.94M | -$144.72M | -$314.84M | -19.4% |
| Depreciation & amortisation | $17.62M | $20.45M | $18.48M | $30.19M | -13.9% |
| Stock-based compensation | $7.63M | $3.00M | $1.33M | $3.19M | +154.1% |
| Change in working capital | $4.39M | $14.09M | $34.45M | $33.81M | -68.8% |
| Operating cash flow | -$416.78M | -$341.58M | -$223.79M | -$202.46M | -22.0% |
| Capital expenditure | -$1.97M | -$2.15M | -$19.16M | -$14.40M | +8.2% |
| Investing cash flow | $662.18M | $978.91M | $229.48M | -$1.15B | -32.4% |
| Share buybacks | -$81.58M | -$98.53M | -$78.96M | $0 | +17.2% |
| Financing cash flow | $345.23M | -$103.51M | -$81.50M | -$1.42M | +433.5% |
| Free cash flow | -$418.75M | -$343.73M | -$242.95M | -$216.87M | -21.8% |
| End cash position | $1.44B | $864.33M | $330.12M | $403.77M | +67.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $1.44B | $1.58B | $865.73M | -8.7% |
| Cash & short-term investments | $1.90B | $1.80B | $1.95B | +5.8% |
| Accounts receivable | $223.00K | $408.00K | $152.00K | -45.3% |
| Inventory | $1.87M | $4.82M | $4.37M | -61.1% |
| Total current assets | $1.92B | $1.82B | $1.97B | +5.4% |
| Property, plant & equipment | $46.96M | $51.99M | $57.20M | -9.7% |
| Goodwill & intangibles | $10.29M | $10.91M | $12.12M | -5.8% |
| Total assets | $2.07B | $2.00B | $2.12B | +3.5% |
| Total current liabilities | $127.59M | $125.13M | $153.05M | +2.0% |
| Total debt | $5.16M | $4.27M | $7.63M | +20.9% |
| Total liabilities | $132.26M | $129.00M | $158.41M | +2.5% |
| Retained earnings | -$1.84B | -$1.56B | -$1.48B | -17.4% |
| Shareholder equity | $1.93B | $1.87B | $1.97B | +3.6% |
| Working capital | $1.79B | $1.70B | $1.82B | +5.6% |
| Net tangible assets | $1.92B | $1.86B | $1.95B | +3.6% |
| Shares issued | 998.96M | 969.43M | 1.01B | +3.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
10.39
-3.57% from price
SMA 20
9.89
+1.36% from price
SMA 50
10.01
+0.09% from price
SMA 100
12.91
-22.37% from price
SMA 200
13.26
-24.42% from price
EMA 12
10.15
-1.31% from price
EMA 26
10.10
-0.83% from price
EMA 50
10.60
-5.51% from price
RSI (14)
48.9
Neutral
MACD (12,26,9)
0.05
Hist 0.04
ATR (14)
0.66
6.59% of price
Realised vol 30D
87.7%
Annualised
Bollinger upper
11.47
20, 2σ
Bollinger lower
8.30
20, 2σ
50 / 200 cross
Death
10.01 vs 13.26
Trend bias
Below 200
-24.42%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.30
Less volatile than market
Correlation to SPY
-0.05
Largely independent
Realised vol 30D
87.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-56.4%
Peak to trough
Max drawdown 5Y
-88.6%
Peak to trough
ATR 14
0.66
6.59% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
What Happens When Social Security Takes Your Benefits Because You Work Too Much?
Motley Fool · 8m ago
Carney warned about economic coercion. Now Trump is testing the Canadian prime minister
Associated Press · 17m ago
Alibaba Launches Record $10 Billion Share Sale to Enter the AI Race
BeInCrypto · 20m ago
Pershing Square (PS) Following Earnings Loss And New Venture Launch Faces A Valuation Test
Simply Wall St. · 21m ago
Tenet Healthcare (THC) Stock May Be 49% Undervalued After Raised Outlook
Simply Wall St. · 21m ago
Morgan Housel warns of a looming career threat for your child
TheStreet · 21m ago
History Says You Should Know These 3 Things Before Buying the Vanguard S&P 500 ETF (VOO)
Motley Fool · 23m ago
He Camped One Weekend on Riverfront Land Inside His IRA. Medicare Charged Him for It Two Years Later.
24/7 Wall St. · 26m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.